In The News
HWL Ebsworth ex-partner asks High Court to overturn age-related expulsion
Munich Re can bring fresh claims in $700M case against AMP
Lundbeck, Sandoz end long-running Lexapro patent war
Giles George has good case for lien over costs in barrister’s case: judge
NSW loses bid to strike out class action’s ‘amorphous’ exemplary damages claim
Novartis unit sues GenesisCare over cancer treatment patent
ASIC still has ‘grave concerns’ over businessman’s plans amid $35M probe
Origin faces shareholder class action over energy markets guidance
Law firm might drop iPhone class action against Apple, court told
$20M settlement in NAB class action OK’d despite concerns over lawyers’ fees
Please login to bookmark Close

Save (0) Please login to bookmark Close Username or Email Address Password Remember Me Australian cancer care company GenesisCare has been sued by Novartis unit Endocyte for allegedly infringing the patents for its prostate cancer treatment Pluvicto. The lawsuit, filed in the Federal Court in January, accuses GenesisCare of infringing or threatening to infringe patents…

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au